Agile Therapeutics, Inc. (AGRX)
Chart Events
Performance Outlook
| Previous Close | 1.0800 |
| Open | 1.0300 |
| Bid | 0.0000 x 3200 |
| Ask | 0.0000 x 4000 |
| Day's Range | 1.0000 - 1.0300 |
| 52 Week Range | 0.9300 - 3.7700 |
| Volume | 688,700 |
| Avg. Volume | 898,242 |
| Market Cap | 89.146M |
| Beta (5Y Monthly) | 0.98 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6990 |
| Earnings Date | Nov 10, 2021 - Nov 15, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.00 |
- GlobeNewswire
Agile Therapeutics to Participate in Upcoming Investor Conferences
PRINCETON, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that management will present and participate at the following virtual investor conferences during the month of September 2021. H.C. Wainwright 23rd Annual Global Investment Conference (September 13-15, 2021) Date: On-Demand Beginning Monday, September 13, 2021 at 7 a.m. ETWebcast: https://journey.ct.events/view/f135776a-907f-4644-bb11-7c4619d6cabf Oppenheimer
- GlobeNewswire
Agile Therapeutics Partners with Telehealth Service, Pandia Health, to Increase Women’s Access to Twirla® (levonorgestrel and ethinyl estradiol) transdermal system
Pandia Health is a doctor founded and led telehealth company, offering online prescriptions and free delivery designed to make it easier for women to access birth control options that meet their needsPartnership represents first telehealth alliance for Agile’s Twirla® birth control patch PRINCETON, N.J., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced a partnership with Pandia Health, an online telehealth service, which wil
- Motley Fool
Agile Therapeutics (AGRX) Q2 2021 Earnings Call Transcript
Before we start, let me remind you that today's call will include forward-looking statements based on current expectations, including statements concerning our financial outlook for the future, management's expectations for our future financial and operational performance, our business strategy, our assessment of the combined hormonal contraceptive market and the potential market share for Twirla, among other statements regarding our plans, prospects, and expectations. Such statements represent our judgments as of today, are not promises or guarantees, and may involve risks and uncertainties that may cause actual results to differ from the results discussed in the forward-looking statements.
